Alzamend Neuro, Inc. (ALZN)
$1.68-$0.01 (-0.30%) Today
Milton C. Ault IIIMilton C. Ault IIIMilton C. Ault IIIMilton C. Ault IIIMilton C. Ault IIIMilton C. Ault IIIAlzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 9 | 1,012,500 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
22 Form 4 filings on record, the earliest from May 12, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Hyperscale Data, Inc. - Director | Grant or award | Series D Convertible Preferred Stock | 7,500 | $1,000.00 | $7.50M | |
| Hyperscale Data, Inc. - Director | Grant or award | Series D Convertible Preferred Stock | 7,500 | $1,000.00 | $7.50M | |
| Milton C. Ault III - Director | Grant or award | Series D Convertible Preferred Stock | 7,500 | $1,000.00 | $7.50M | |
| Henry Carl Nisser - Officer | Grant or award | Stock Options (Right to Buy) | 60,000 | $0.00 | - | |
| William B. Horne - Director | Grant or award | Stock Options (Right to Buy) | 60,000 | $0.00 | - | |
| Jeffrey Oram - Director | Grant or award | Stock Options (Right to Buy) | 60,000 | $0.00 | - | |
| Mark Gustafson - Director | Grant or award | Stock Options (Right to Buy) | 60,000 | $0.00 | - | |
| Stephan Jackman - Officer | Grant or award | Stock Options (Right to Buy) | 450,000 | $0.00 | - | |
| David J. Katzoff - Officer | Grant or award | Stock Options (Right to Buy) | 300,000 | $0.00 | - | |
| Milton C. Ault III | Open-market purchase | Common Stock | 108,388 | $1.00 | $109K | |
| Lynne Fahey McGrath | Open-market sale | Common Stock | 30 | $2.29 | $69 | |
| Milton C. Ault III | Other | Common Stock | 61,743 | $2.32 | $143K | |
| Milton C. Ault III | Open-market sale | Common Stock | 20,397 | $2.32 | $47K | |
| Milton C. Ault III | Open-market sale | Common Stock | 101,394 | $2.44 | $247K | |
| Milton C. Ault III | Other | Series B Convertible Preferred Stock | 143.24 | $1,000.00 | $143K | |
| Milton C. Ault III | Other | Common Stock | 100,000 | $2.32 | $232K | |
| Milton C. Ault III | Open-market sale | Common Stock | 82,033 | $2.45 | $201K | |
| Milton C. Ault III | Other | Common Stock | 100,000 | $2.32 | $232K | |
| Milton C. Ault III | Open-market sale | Common Stock | 57,379 | $2.49 | $143K | |
| Milton C. Ault III | Other | Series B Convertible Preferred Stock | 232 | $1,000.00 | $232K | |
| Milton C. Ault III | Other | Series B Convertible Preferred Stock | 232 | $1,000.00 | $232K | |
| Milton C. Ault III | Open-market sale | Common Stock | 20,686 | $2.39 | $50K | |
| Milton C. Ault III | Other | Common Stock | 100,000 | $2.32 | $232K | |
| Milton C. Ault III | Open-market sale | Common Stock | 36,777 | $2.35 | $86K | |
| Milton C. Ault III | Open-market sale | Common Stock | 65,903 | $2.44 | $161K | |
| Milton C. Ault III | Other | Series B Convertible Preferred Stock | 232 | $1,000.00 | $232K | |
| Milton C. Ault III | Open-market sale | Common Stock | 37,738 | $2.31 | $87K | |
| Milton C. Ault III | Open-market sale | Common Stock | 38,324 | $2.31 | $88K | |
| Milton C. Ault III | Open-market sale | Common Stock | 3,566 | $2.33 | $8K | |
| Milton C. Ault III | Open-market sale | Common Stock | 77,009 | $2.35 | $181K | |
| Milton C. Ault III | Other | Common Stock | 100,000 | $2.32 | $232K | |
| Milton C. Ault III | Other | Series B Convertible Preferred Stock | 232 | $1,000.00 | $232K | |
| Milton C. Ault III | Open-market sale | Common Stock | 43,238 | $2.38 | $103K | |
| Milton C. Ault III | Open-market sale | Common Stock | 39,140 | $2.31 | $90K | |
| Milton C. Ault III | Open-market sale | Common Stock | 14,628 | $2.31 | $34K | |
| Milton C. Ault III | Other | Common Stock | 100,000 | $2.32 | $232K | |
| Milton C. Ault III | Other | Series B Convertible Preferred Stock | 232 | $1,000.00 | $232K | |
| Milton C. Ault III | Other | Common Stock | 100,000 | $2.32 | $232K | |
| Milton C. Ault III | Open-market sale | Common Stock | 2,121 | $2.45 | $5K | |
| Milton C. Ault III | Open-market sale | Common Stock | 20,870 | $2.47 | $51K | |
| Milton C. Ault III | Other | Series B Convertible Preferred Stock | 232 | $1,000.00 | $232K | |
| Milton C. Ault III | Other | Common Stock | 100,000 | $2.32 | $232K | |
| Milton C. Ault III | Open-market sale | Common Stock | 29,449 | $2.51 | $74K | |
| Milton C. Ault III | Open-market sale | Common Stock | 100,000 | $2.22 | $222K | |
| Milton C. Ault III | Other | Series B Convertible Preferred Stock | 232 | $1,000.00 | $232K | |
| Milton C. Ault III | Open-market sale | Common Stock | 36,532 | $2.90 | $106K | |
| Milton C. Ault III | Open-market sale | Common Stock | 8,311 | $2.68 | $22K | |
| Milton C. Ault III | Other | Common Stock | 143,429 | $2.32 | $333K | |
| Milton C. Ault III | Open-market sale | Common Stock | 59,516 | $2.95 | $176K | |
| Milton C. Ault III | Open-market sale | Common Stock | 9,621 | $2.93 | $28K | |
| Milton C. Ault III | Other | Series B Convertible Preferred Stock | 332.76 | $1,000.00 | $333K | |
| Milton C. Ault III | Open-market sale | Common Stock | 1,213 | $5.06 | $6K | |
| Milton C. Ault III | Open-market sale | Common Stock | 11 | $5.28 | $58 |
Alzamend Neuro, Inc. (ALZN) had 9 insider filings in the last 90 days, with the most recent on 2026-08-21. The full record for ALZN runs to 22 Form 4 filings, the earliest from 2025-05-12. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ALZN were filed in the last 90 days. 1 purchase is on record for this company.
No insider sales of ALZN were filed in the last 90 days. 25 sales are on record for this company.
This page tracks ALZN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ALZN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
